stockrowCorcept Therapeutics Incorporated
CORT Healthcare Biotechnology
Corcept Therapeutics Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $761.4 million, up 12.8% from fiscal 2024.
- Revenue
- +64.0%
- EPS
- +525.8%
- Free cash flow
- +161.0%
Quarter to September 2026, against a year earlier
Follow CORT
Alert me
Corcept Therapeutics Incorporated (CORT) Total debt
Corcept Therapeutics Incorporated's total debt at the end of fiscal 2025 was $5.0M, down 17.8% from $6.1M in fiscal 2024. Over the past ten years it has ranged from $501.0K (fiscal 2020) to $14.7M (fiscal 2016); the current reading is higher than 63% of that period. Corcept Therapeutics Incorporated ranks 285th of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $5.0M | (17.75%) |
| FY2024 | $6.1M | 434.30% |
| FY2022 | $1.1M | 117.30% |
| FY2021 | $526.0K | 4.99% |
| FY2020 | $501.0K | (73.67%) |
| FY2019 | $1.9M | (87.02%) |
| FY2016 | $14.7M | 17.05% |
| FY2015 | $12.5M | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Dec 2025 | $5.0M | (5.37%) |
| Sep 2025 | $5.3M | (13.08%) |
| Dec 2024 | $6.1M | (3.96%) |
| Sep 2024 | $6.4M | 2,726.22% |
| 27 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| ARWR Arrowhead Pharmaceuticals, Inc. compare | $864.1M |
| SYRE Spyre Therapeutics, Inc. compare | $387.1M |
| MDGL Madrigal Pharmaceuticals, Inc. compare | $341.3M |
| CYTK Cytokinetics, Incorporated compare | $174.4M |
| KRYS Krystal Biotech, Inc. compare | $8.3M |
| CORT Corcept Therapeutics Incorporated | $5.0M |
| PRAX Praxis Precision Medicines, Inc. compare | $2.8M |
| PTGX Protagonist Therapeutics, Inc. compare | $1.8M |
| ABVX Abivax SA Sponsored ADR compare | $1.4M |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on CORT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement